A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Enzalutamide (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 15 Mar 2017 Planned End Date changed from 1 Jan 2018 to 1 May 2019.
- 15 Mar 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Dec 2017.
- 15 Mar 2017 Status changed from recruiting to active, no longer recruiting.